Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children
Launched by GLAXOSMITHKLINE · Aug 6, 2010
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- For confirmed cases:
- • A male or female child born after 01 October 2006 and at least 14 weeks of age at the time of hospital admission.
- • Child admitted at the study hospital for SGE during the study period.
- • Onset of SGE ≤ 14 days prior to admission.
- • Written informed consent obtained and signed from the parent or guardian of the child.
- • Stool samples collected during the first 48 hours of hospitalisation and then tested positive for RV by PCR.
- For controls:
- • A male or female child born after 01 October 2006 and at least 14 weeks of age at the time of the hospital admission or visit to the hospital outpatient clinic.
- • Hospitalised or visiting the hospital outpatient clinic for non-GE causes at the same hospital during the same time-period, as the probable case.
- • Born within ±2 weeks from the date of birth of the case. If the list of children born within ±2 weeks is exhausted, then the range will be extended to ±4 weeks. In case a suitable control is not found even then, the range will be extended to ±6 weeks.
- • Written informed consent obtained and signed from the parent or guardian of the child.
- Exclusion Criteria:
- For cases:
- • Child has previously participated as a case or a control in this study, either in the same hospital or in another study hospital.
- • Onset of SGE \>48 hours after admission to the hospital (nosocomial infections).
- • Child with a condition where rotavirus vaccination would be contraindicated.
- For controls:
- • Child has participated in the past as a case or control in this study, either in the same hospital or in another study hospital.
- • Child who has symptoms of GE/ SGE during current hospital stay/ visit to the hospital outpatient clinic or on the day of interview of his/her parent or guardian.
- • Child with a condition where rotavirus vaccination would be contraindicated.
About Glaxosmithkline
GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edegem, , Belgium
Antwerpen, , Belgium
Gent, , Belgium
Hasselt, , Belgium
Kortrijk, , Belgium
Mons, , Belgium
Wilrijk, , Belgium
Genk, , Belgium
Ottignies, , Belgium
Bruxelles, , Belgium
Gosselies, , Belgium
Merksem, , Belgium
Namur, , Belgium
Oostende, , Belgium
Deurne, , Belgium
Hornu, , Belgium
Deinze, , Belgium
Roeselaere, , Belgium
Chimay, , Belgium
Eeklo, , Belgium
Heusden, , Belgium
Ieper, , Belgium
Nivelles, , Belgium
Sint Niklaas, , Belgium
Sint Truiden, , Belgium
Tongeren, , Belgium
Patients applied
Trial Officials
GSK Clinical Trials
Study Director
GlaxoSmithKline
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials